Nalaganje...
Alemtuzumab in the treatment of multiple sclerosis
Alemtuzumab (formerly known as Campath-1H) has recently been approved by the European Medicines Agency for highly-active, relapsing-remitting multiple sclerosis (MS). The molecule targets the CD52 surface glycoprotein on certain T cells and B cells and is thought to exert its effect in MS through a...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3959804/ https://ncbi.nlm.nih.gov/pubmed/24672254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JIR.S38079 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|